Difference between revisions of "Part:BBa K4165150"
| Line 9: | Line 9: | ||
This part is derived from D-enantiomeric peptide its amino acid sequence is APTLLRLHSLGA, that can bind to PHF seed (VQIVYK), its half maximal concentration for tau fibril formation inhibition is 139.6 μM. In addition, it has low cell penetration ability. | This part is derived from D-enantiomeric peptide its amino acid sequence is APTLLRLHSLGA, that can bind to PHF seed (VQIVYK), its half maximal concentration for tau fibril formation inhibition is 139.6 μM. In addition, it has low cell penetration ability. | ||
| − | + | <span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span> | |
| + | <partinfo>BBa_K4165150 SequenceAndFeatures</partinfo> | ||
===Dry Lab=== | ===Dry Lab=== | ||
| Line 32: | Line 33: | ||
<!-- --> | <!-- --> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
===References=== | ===References=== | ||
1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432. | 1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432. | ||
Revision as of 17:05, 10 October 2022
APT Peptide
Tau binding peptide targeting the PHF seed of Tau
Usage and Biology
This part is derived from D-enantiomeric peptide its amino acid sequence is APTLLRLHSLGA, that can bind to PHF seed (VQIVYK), its half maximal concentration for tau fibril formation inhibition is 139.6 μM. In addition, it has low cell penetration ability.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Dry Lab
Modeling
APT were modeled by AlphaFold2, Apptest, ITASSER and RosettaFold. best model is obtained from AlphaFold2 and the model is shown below
Figure 1.: Predicted 3D structure of Synthetic peptide APT.
Table 1: Quality assessment parameters of TLKIVW model.
References
1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.